PRECISION Study: A phase II prospective, mono-center, randomized, double-blinded, controlled trial to assess the efficacy of local iloprost therapy to promote bone healing in patients at risk for fracture non-union

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-527568-34-00

Enrollment

Registered

2026-10-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bone fracture in patients identified as being at high risk of impaired fracture healing based on elevated pre-operative CD8+ T effector memory cells re-expressing CD45RA (TEMRA) levels

Brief summary

Radiological fracture healing at Week 18 assessed by CT

Detailed description

Radiological fracture healing at Week 18 and Week 36 (RUSH, mRUST, X-ray), Patient-reported outcomes at week 6, 18, 36, 52 (VAS pain score, EQ-5D-5L, SMFA, Return-to-work status), Incidence, severity and relationship of AEs graded according to NCI-CTCAE V6.0

Interventions

DRUGIlomedin® 20 μg/1 ml

DRUGKonzentrat zur Herstellung einer Infusionslösung

DRUGIsotone Kochsalz-Lösung 0

DRUG9 % Braun Infusionslösung

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Radiological fracture healing at Week 18 assessed by CT	—

Secondary

Measure	Time frame
Radiological fracture healing at Week 18 and Week 36 (RUSH, mRUST, X-ray), Patient-reported outcomes at week 6, 18, 36, 52 (VAS pain score, EQ-5D-5L, SMFA, Return-to-work status), Incidence, severity and relationship of AEs graded according to NCI-CTCAE V6.0	—

Outcome results

None listed

Source: EU CTIS · Data processed: Oct 14, 2026